

Yoshinori Ohsumi's Nobel Prize for mechanisms of autophagy: from basic yeast biology to therapeutic potential

¹RA Frake, ²DC Rubinsztein

¹MB/PhD Student, ²Professor of Molecular Neurogenetics, Department of Medical Genetics, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Cambridge Biomedical Campus, Cambridge, UK

ABSTRACT On 3 October 2016, Japanese cell biologist Yoshinori Ohsumi was awarded the Nobel Prize in Physiology or Medicine 'for his discoveries of mechanisms for autophagy'; autophagy being an intracellular degradation pathway that helps maintain cytoplasmic homeostasis. This commentary discusses Ohsumi's Nobel prize-winning work in context, before explaining the clinical relevance of autophagy.

Correspondence to DC Rubinsztein
 Department of Medical Genetics
 Cambridge Institute for Medical Research
 Cambridge Biomedical Campus
 Hills Road
 Cambridge CB2 0XY
 UK

e-mail dcr1000@cam.ac.uk

KEYWORDS autophagy, yeast genetics, Yoshinori Ohsumi

DECLARATION OF INTERESTS No conflict of interests declared

INTRODUCTION

Macroautophagy (hereafter referred to as autophagy) is an important means of maintaining cellular homeostasis by trafficking cytoplasmic material for enzymatic degradation in the lysosome. In mammalian cells, the process involves formation of a cup-shaped, double-membraned phagophore (or isolation membrane), which closes around cytoplasmic material to form a spherical, double-membraned autophagosome (Figure 1a). The autophagosome outer membrane ultimately fuses with a lysosome to form an autolysosome, resulting in degradation of the inner autophagosome membrane and sequestered cargo. Autophagy is both a constitutive process and subject to dynamic regulation by a range of physiological signals. Notably, autophagy is induced by nutrient starvation. The substrates of autophagy are extremely diverse, ranging from organelles such as mitochondria, through to aggregate-prone proteins and invading microorganisms.

CHARACTERISATION OF AUTOPHAGY IN YEAST

Yoshinori Ohsumi's first contribution to autophagy research demonstrated that autophagy in yeast is similar to that in mammalian cells (Figure 1b). He and colleagues observed that when the yeast *Saccharomyces cerevisiae* undergoes nutrient starvation, cytoplasmic components are delivered to the vacuole, equivalent to the mammalian lysosome, in which they appear as single-membraned autophagic bodies.¹ Later, the group used electron microscopy to identify and characterise double-membraned autophagosomes as the precursors of autophagic bodies in yeast.² Autophagic bodies are the remains of autophagosomes after fusion with the

vacuole; these intermediate structures are visible in yeast, but not in mammalian cells.

EARLY DESCRIPTIONS OF AUTOPHAGY IN MAMMALIAN CELLS

By the time Ohsumi began working in yeast, the study of autophagy in mammalian cells had already been underway for several decades. An earlier recipient of the Nobel Prize in Physiology or Medicine, Christian de Duve, is considered by many as the founding father of autophagy research.³ de Duve coined the term 'autophagy' in 1963 to describe single- and double-membraned vacuoles containing cytoplasmic components observed by electron microscopy.⁴ Per Seglen and colleagues made major contributions to the emerging field of autophagy. For example, Seglen helped characterise the cup-shaped phagophore, which closes to form the autophagosome.⁵

REGULATION OF MAMMALIAN AUTOPHAGY

The response of autophagy to various physiological stimuli was also investigated in these early days, with de Duve and colleagues reporting that administering glucagon to rats upregulates autophagy in the liver.⁶ This observation fits with autophagy induction in response to nutrient starvation as a means of producing amino acids for gluconeogenesis and other metabolic pathways; a hypothesis that was borne out almost a decade later, when amino acid depletion was shown to upregulate autophagy in both cultured human cells and rat liver.^{7,8} Analysis of the signalling events linking nutrient starvation to autophagy induction was to follow. A breakthrough came when Alfred Meijer's group, working in hepatocytes isolated from starved rats, noted that




FIGURE 1 Autophagy pathway in mammalian cells and yeast. (a) In mammalian cells, the phagophore closes around cytoplasmic material to form a spherical, double-membraned autophagosome. The autophagosome outer membrane fuses with a lysosome to form an autolysosome, resulting in degradation of the inner autophagosome membrane and sequestered cargo. (b) The pathway is similar in yeast, except that the autophagosome outer membrane fuses with the vacuole. This fusion event forms single-membraned autophagic bodies within the vacuole that are degraded, together with the sequestered cargo.

phosphorylation of ribosomal protein S6 paralleled the decrease in autophagy observed when amino acids were added to the culture medium. The immunosuppressive drug rapamycin, which indirectly inhibits S6 phosphorylation by antagonising mTOR (mammalian target of rapamycin) function, was then shown to induce autophagy.⁹ This work uncovered the role of mTOR signalling in autophagy regulation and established rapamycin as the first drug in the expanding class of autophagy inducers.

MOLECULAR MECHANISMS OF AUTOPHAGY

The morphology and regulation of autophagy were therefore beginning to be understood, yet none of the molecular machinery was known. At this point Ohsumi and colleagues performed their first pioneering screens. The group used yeast lacking vacuolar proteases, which normally accumulate autophagic bodies under nutrient starvation, to identify 15 autophagy-defective mutant yeast strains that failed to form autophagic bodies. In this way, they initially identified 15 novel autophagy genes (now referred to as ATG genes).¹⁰ Shortly afterwards, other groups, such as those of Daniel Klionsky and Michael Thumm, published genetic screens in yeast, which contributed to the growing list of ATG genes.^{11–13} ATG1 was the first such gene to be characterised by Ohsumi and colleagues. The kinase

activity of the encoded protein (Atg1p) was found to be essential for autophagy, since genetic reconstitution with 'kinase-dead' mutant ATG1 cannot rescue the autophagy-deficient phenotype of ATG1 mutant yeast. Moreover, the phosphorylation status of Atg1p was shown to be regulated by nutrient availability, leading the authors to speculate (as has since been established) that the protein plays a key role in autophagy induction in response to nutrient starvation.¹⁴ The Ohsumi group also demonstrated that inhibiting TOR with rapamycin induces autophagy in yeast, as previously shown in mammalian cells,⁹ and that TOR signalling is upstream of the Atg proteins.¹⁵ This suggests significant commonalities between autophagy regulation in yeast and mammalian cells, which have subsequently been utilised by many in autophagy research. Indeed, much pioneering work has been conducted in mammalian systems by Tamotsu Yoshimori and Noboru Mizushima, both of whom trained with Ohsumi.

UBIQUITIN-LIKE CONJUGATION SYSTEMS IN AUTOPHAGY

Investigations then began into how the Atg proteins interact. Despite having no apparent homology to ubiquitin, Atg12p was shown to covalently bind Atg5p in much the same way as ubiquitin tags substrates (Figure 2a). In wild-type yeast, most Atg5p/Atg12p was found as




FIGURE 2 Ubiquitin-like conjugation systems in yeast autophagy. (a) The first conjugation reaction, the carboxyl-terminal glycine of Atg12p is activated by Atg7p. Atg12p is then transferred to Atg10p and finally onto Atg5p. The final Atg5p-Atg12p/Atg16p complex is formed when Atg16p binds Atg5p. (b) In the second conjugation reaction, Atg4p first cleaves nascent Atg8p to reveal a carboxyl-terminal glycine. Atg8p is then activated by Atg7p, transferred to Atg3p and finally onto the membrane component phosphatidylethanolamine (PE). Homologous proteins undergo equivalent conjugation reactions in mammalian autophagy.

an Atg5p-Atg12p conjugate, yet this was not the case in ATG7 and ATG10 mutant yeast. The Ohsumi group generated a series of yeast strains with targeted mutations to discover how this conjugate forms; first, the carboxyl-terminal glycine of Atg12p is activated by Atg7p, then Atg12p is transferred to Atg10p and finally onto Atg5p.^{16,17} Around the same time, Klionsky's lab showed that Atg7p functions at the substrate sequestration step of autophagosome formation.¹⁸ These studies lead to identification of the first mammalian ATG genes; human *ATG12* and *ATG5*, which conjugate via reactions analogous to those in yeast and are expressed across the full range of human tissues.¹⁹ Next, Ohsumi and colleagues described Atg16p as the third member of the Atg5p-Atg12p complex. The *ATG16* gene had been missed in their initial screen, but was identified via a secondary screen for Atg12p binding partners. Atg16p was shown to bind Atg5p directly (and thereby Atg12p indirectly) and play a key role in autophagy initiation, possibly by forming Atg5p-Atg12p/Atg16p multimers.²⁰

Two years later, a second ubiquitin-like conjugation system was discovered (Figure 2b), with Atg8p as the ubiquitin-like protein.²¹ Ohsumi and colleagues had in fact already identified Atg8p as a marker of autophagic structures in yeast²² and this new discovery explains

how the hydrophilic protein Atg8p is able to associate with autophagic membranes. The reaction begins with Atg4p cleaving nascent Atg8p to reveal a carboxyl-terminal glycine.²¹ Next Atg8p is activated by Atg7p (just as Atg12p), transferred to Atg3p and finally onto the membrane component phosphatidylethanolamine.²³ This lipidation reaction, the first example of a protein conjugating to a membrane phosphoglycerolipid, is central to membrane dynamics in autophagy. The Yoshimori lab then identified LC3 (short for microtubule-associated protein 1 light chain 3) as the mammalian homologue of Atg8p. Two forms were described; non-lipidated LC3-I in the cytosol and phosphatidylethanolamine-conjugated LC3-II on autophagic membranes.²⁴ The amount of LC3-II was found to parallel autophagosome numbers and has gone on to become the canonical readout of autophagy in mammalian cells.²⁵

AUTOPHAGY IN HEALTH AND DISEASE

With Ohsumi's work having facilitated the molecular dissection of autophagy, several groups began to focus on clinically-relevant aspects of the process. (see Figure 3 for timeline). The seminal work linking autophagy to cancer was performed by Beth Levine's group, who identified Beclin 1 as the human homologue of yeast




FIGURE 3 Timeline of autophagy research. Schematic showing how the autophagy field has developed; from when the term was first coined, to current research on autophagy in human health and disease.

Atg6p. *BECN1* is described as a tumour suppressor in breast cancer, with monoallelic deletions and decreased expression observed in patient samples. Genetic reconstitution of MCF7 human breast cancer cells, which do not express detectable Beclin 1, is reported to restore autophagy induction in response to nutrient starvation and promote a less malignant phenotype.²⁶ In this way, autophagy is suggested to inhibit tumorigenesis. Over time the picture has become more complicated as, while maintenance of cellular homeostasis by autophagy can protect against malignant transformation, autophagy also drives resistance to conditions that cause cell death (hypoxia, for instance) and thereby promotes metastatic tumour progression.²⁷ Such complexity is illustrated by the roles of established oncogenes and tumour suppressors in autophagy. XIAP and cIAP1 (overexpressed in several human cancers) induce autophagy by upregulating transcription of Beclin 1²⁸ and reduced expression of the proto-oncogene *MYC* impairs autophagosome formation.²⁹ On the other hand, the tumour suppressor *PTEN* positively regulates autophagy.³⁰

Autophagy is also implicated in infection and immunity, with the degradation of intracellular bacteria by autophagy (referred to as xenophagy) being possibly the most ancient form of defence against invading microorganisms. Xenophagy was first studied in the labs of Yoshimori and Vojo Deretic. The Yoshimori group demonstrated that autophagy could eliminate group A *Streptococcus* from infected HeLa cells³¹ and this was followed almost immediately by Deretic and colleagues' report that autophagy induction in macrophages

infected with *Mycobacterium tuberculosis* promotes clearance of the pathogen.³² Autophagy is now thought to have additional immunologic roles, such as modulating inflammation and influencing lymphocyte development and function.³³ For instance, single-nucleotide polymorphisms in the core autophagy gene *ATG16L1* have been identified by genome-wide association studies as susceptibility loci for Crohn's disease,^{34,35} with *Atg16L1*-deficient mice showing much worse colitis pathology compared with wild-type controls.³⁶

Autophagy has also been identified as a potential therapeutic target in neurodegenerative disease. The functional link between autophagy and neurodegeneration was first established when we published that upregulating autophagy promotes the degradation of polyglutamine-expanded huntingtin, the toxic protein in Huntington's disease.³⁷ This finding has since been translated into animal models, with autophagy induction ameliorating neurodegenerative pathology in a mouse model of Huntington's disease.³⁸ A protective role for autophagy has subsequently been described in many other neurodegenerative diseases, predominantly via the clearance of intracytoplasmic aggregate-prone proteins, such as alpha-synuclein in Parkinson's disease and tau in various neurodegenerative conditions.³⁹ Impaired autophagy has also been shown to predispose to neurodegeneration, as highlighted by mouse studies demonstrating autophagy is essential for neuronal survival. Mice lacking *Atg7* in the central nervous system suffer massive neuronal loss in the cerebral and cerebellar cortices⁴⁰ and those lacking *Atg5* develop

progressive motor function deficits, which are attributed to neurodegeneration.⁴¹ Several human neurodegenerative conditions have since been linked to autophagic dysfunction, some directly caused by mutations in autophagy genes. Most recently, a homozygous missense mutation in *ATG5* was identified that impairs autophagy and causes ataxia with developmental delay in affected patients.⁴²

CONCLUDING REMARKS

Building on what was already known about the morphology and regulation of autophagy in mammalian cells, the pioneering work Ohsumi performed in yeast gave researchers a toolkit with which to dissect the molecular machinery of autophagy. This has facilitated greater understanding of autophagy in human health

and disease, especially in the fields of cancer, immunology and neurodegeneration. The hope is that autophagy will become an ever more tractable therapeutic target, with autophagy modulators moving into mainstream clinical practice.

ACKNOWLEDGMENTS

We are grateful for support from a Wellcome Trust Principal Research Fellowship (to DC Rubinsztein; 095317/Z/11/Z), a Wellcome Trust Strategic Grant (100140/Z/12/Z), a Sims Scholarship (to RA Frake), the NIHR Biomedical Research Centre at Addenbrooke's Hospital, and the Tau Consortium.

REFERENCES

- 1 Takeshige K, Baba M, Tsuboi S et al. Autophagy in yeast demonstrated with proteinase-deficient mutants and conditions for its induction. *J Cell Biol* 1992; 119: 301–11.
- 2 Baba M, Takeshige K, Baba N et al. Ultrastructural analysis of the autophagic process in yeast: detection of autophagosomes and their characterization. *J Cell Biol* 1994; 124: 903–13.
- 3 Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. *Nat Rev Mol Cell Biol* 2007; 8: 931–7.
- 4 De Duve C, Wattiaux R. Functions of lysosomes. *Annu Rev Physiol* 1966; 28: 435–92.
- 5 Seglen P. *Lysosomes: Their Role in Protein Breakdown*. Florida: Academic Press; 1987.
- 6 Deter RL, Baudhuin P, De Duve C. Participation of lysosomes in cellular autophagy induced in rat liver by glucagon. *J Cell Biol* 1967; 35: C11–6.
- 7 Mitchener JS, Shelburne JD, Bradford WD et al. Cellular autophagy induced by deprivation of serum and amino acids in HeLa cells. *Am J Pathol* 1976; 83: 485–92.
- 8 Mortimore GE, Schworer CM. Induction of autophagy by amino-acid deprivation in perfused rat liver. *Nature* 1977; 270: 174–6.
- 9 Blommaert EF, Luiken JJ, Blommaert PJ, et al. Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes. *J Biol Chem* 1995; 270: 2320–6.
- 10 Tsukada M, Ohsumi Y. Isolation and characterization of autophagy-defective mutants of *Saccharomyces cerevisiae*. *FEBS Lett* 1993; 333: 169–74.
- 11 Klionsky DJ, Cregg JM, Dunn WA, Jr. et al. A unified nomenclature for yeast autophagy-related genes. *Dev Cell* 2003; 5: 539–45.
- 12 Thumm M, Egner R, Koch B et al. Isolation of autophagocytosis mutants of *Saccharomyces cerevisiae*. *FEBS Lett* 1994; 349: 275–80.
- 13 Harding TM, Morano KA, Scott SV et al. Isolation and characterization of yeast mutants in the cytoplasm to vacuole protein targeting pathway. *J Cell Biol* 1995; 131: 591–602.
- 14 Matsuura A, Tsukada M, Wada Y et al. Apg1p, a novel protein kinase required for the autophagic process in *Saccharomyces cerevisiae*. *Gene* 1997; 192: 245–50.
- 15 Noda T, Ohsumi Y. Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. *J Biol Chem* 1998; 273: 3963–6.
- 16 Mizushima N, Noda T, Yoshimori T et al. A protein conjugation system essential for autophagy. *Nature* 1998; 395: 395–8.
- 17 Tanida I, Mizushima N, Kiyooka M et al. Apg7p/Cvt2p: A novel protein-activating enzyme essential for autophagy. *Mol Biol Cell* 1999; 10: 1367–79.
- 18 Kim J, Dalton VM, Eggerton KP et al. Apg7p/Cvt2p is required for the cytoplasm-to-vacuole targeting, macroautophagy, and peroxisome degradation pathways. *Mol Biol Cell* 1999; 10: 1337–51.
- 19 Mizushima N, Sugita H, Yoshimori T et al. A new protein conjugation system in human. The counterpart of the yeast Apg12p conjugation system essential for autophagy. *J Biol Chem* 1998; 273: 33889–92.
- 20 Mizushima N, Noda T, Ohsumi Y. Apg16p is required for the function of the Apg12p-Apg5p conjugate in the yeast autophagy pathway. *EMBO J* 1999; 18: 3888–96.
- 21 Kirisako T, Ichimura Y, Okada H et al. The reversible modification regulates the membrane-binding state of Apg8/Aut7 essential for autophagy and the cytoplasm to vacuole targeting pathway. *J Cell Biol* 2000; 151: 263–76.
- 22 Kirisako T, Baba M, Ishihara N et al. Formation process of autophagosome is traced with Apg8/Aut7p in yeast. *J Cell Biol* 1999; 147: 435–46.
- 23 Ichimura Y, Kirisako T, Takao T et al. A ubiquitin-like system mediates protein lipidation. *Nature* 2000; 408: 488–92.
- 24 Kabeya Y, Mizushima N, Ueno T et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. *EMBO J* 2000; 19: 5720–8.
- 25 Klionsky DJ, Abdalla FC, Abeliovich H et al. Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy* 2012; 8: 445–544.
- 26 Liang XH, Jackson S, Seaman M et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. *Nature* 1999; 402: 672–6.
- 27 Galluzzi L, Pietrocola F, Bravo-San Pedro JM et al. Autophagy in malignant transformation and cancer progression. *EMBO J* 2015; 34: 856–80. <http://dx.doi.org/10.15252/embj.201490784>
- 28 Lin F, Ghislat G, Luo S et al. XIAP and cIAP1 amplifications induce Beclin 1-dependent autophagy through NFκB activation. *Hum Mol Genet* 2015; 24: 2899–913. <http://dx.doi.org/10.1093/hmg/ddv052>
- 29 Toh PP, Luo S, Menzies FM et al. Myc inhibition impairs autophagosome formation. *Hum Mol Genet* 2013; 22: 5237–48. <http://dx.doi.org/10.1093/hmg/ddt381>

- 30 Arico S, Petiot A, Bauvy C et al. The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway. *J Biol Chem* 2001; 276: 35243–6.
- 31 Nakagawa I, Amano A, Mizushima N et al. Autophagy defends cells against invading group A *Streptococcus*. *Science* 2004; 306: 1037–40.
- 32 Gutierrez MG, Master SS, Singh SB et al. Autophagy is a defense mechanism inhibiting BCG and *Mycobacterium tuberculosis* survival in infected macrophages. *Cell* 2004; 119: 753–66.
- 33 Deretic V, Kimura T, Timmins G et al. Immunologic manifestations of autophagy. *J Clin Invest* 2015; 125: 75–84. <http://dx.doi.org/10.1172/JCI73945>
- 34 Rioux JD, Xavier RJ, Taylor KD et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. *Nat Genet* 2007; 39: 596–604.
- 35 Hampe J, Franke A, Rosenstiel P et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. *Nat Genet* 2007; 39: 207–11.
- 36 Saitoh T, Fujita N, Jang MH et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1 beta production. *Nature* 2008; 456: 264–8.
- 37 Ravikumar B, Duden R, Rubinsztein DC. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. *Hum Mol Genet* 2002; 11: 1107–17.
- 38 Ravikumar B, Vacher C, Berger Z et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. *Nat Genet* 2004; 36: 585–95.
- 39 Rubinsztein DC, Bento CF, Deretic V. Therapeutic targeting of autophagy in neurodegenerative and infectious diseases. *J Exp Med* 2015; 212: 979–90. <http://dx.doi.org/10.1084/jem.20150956>
- 40 Komatsu M, Waguri S, Chiba T et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. *Nature* 2006; 441: 880–4.
- 41 Hara T, Nakamura K, Matsui M et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. *Nature* 2006; 441: 885–9.
- 42 Kim M, Sandford E, Gatica D, Qiu Y, Liu X, Zheng Y, et al. Mutation in ATG5 reduces autophagy and leads to ataxia with developmental delay. *Elife* 2016; 5. <http://dx.doi.org/10.7554/eLife.12245>